Deoxycytidine

The R&D of nucleoside antimetabolite drugs has always been one of the core directions in the treatment of hematological malignancies. As a representative precursor compound of pyrimidine nucleoside analogs, deoxycytidine can be embedded into the DNA synthesis process of cells to block the extension of DNA strands in the S phase of the cell cycle, thereby inhibiting the division of rapidly proliferating tumor cells. At present, this component is a key synthetic intermediate for multiple commonly used clinical chemotherapy drugs, and its derivatives are widely used in the treatment of malignant hematological diseases such as acute myeloid leukemia and non-Hodgkin's lymphoma. It can also be used as a synthetic raw material for antiviral drugs, providing a core foundation for the development of clinical medication for related diseases.

At present, the global market size of deoxycytidine API maintains steady growth. The market size in 2023 was approximately USD 120 million, with a compound annual growth rate of around 7%. The growth momentum mainly comes from the continuous expansion of demand for downstream anti-tumor drugs. In terms of the competitive landscape, global production capacity is mainly concentrated in China, India and Europe. Among them, Chinese manufacturers account for more than 60% of the global supply share by virtue of cost and technical advantages. At present, there are more than 10 product specifications of downstream deoxycytidine preparations that have been approved for marketing in China. With the advancement of the consistency evaluation of generic drugs, the demand for APIs continues to rise.

As a key pharmaceutical intermediate, deoxycytidine has no separately marketed original research preparation varieties, and its core compound patent has been publicly available. At present, deoxycytidine APIs from more than 15 domestic enterprises have completed registration with CDE, and some registration numbers are in status A, which can be used in association with domestic preparation applications. Multiple batches of reference preparations of related derivatives have been included in the *List of Chemical Drugs*, and the quality standards of domestic APIs have met the relevant ICH requirements. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for deoxycytidine, most of which are in stock. Orders for in-stock products placed before 16:00 will be shipped on the same day. The products meet the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA, and can fully meet the various reference standard needs of pharmaceutical enterprises in the stages of API R&D, quality research and registration application.